Clinical Trials - November 7, 2023
FluoGuide announces Phase IIa results
The company has announced topline results from the phase IIa trial of its lead product FG001 in guiding surgery in patients with head & neck cancer, confirming positive efficacy and safety. “These encouraging first clinical results, showing that FG001 was able to light up cancer in all head & neck cancer patients in the trial, […]
Clinical Trials - November 7, 2023
Positive data from TILT Biotherapeutics
The company has presented Phase I data on its TILT-123 monotherapy, a T-cell activating oncolytic virus for advanced solid tumor patients, in a late-breaking poster at the Society for Immunotherapy of Cancer 2023 conference. Poster 1 demonstrates the safety profile of TILT-123 monotherapy and showcases promising efficacy results, including anti-tumor activity and the induction of […]
Business - November 2, 2023
Multiple issues need further investigation in SynAct trial
SynAct Pharma has announced evaluation of the 4-week RESOLVE Phase 2a clinical trial in moderate to severely active rheumatoid arthritis patients with an incomplete response to methotrexate. During the evaluation of the unblinded study data SynAct Pharma identified multiple issues that need further investigation before any conclusion on the outcome of the study can be […]
Business - October 31, 2023
Aqilion reports positive Phase I results
The company has reported results from its ARIA-1 study in healthy volunteers with the drug candidate AQ280, a selective proprietary JAK1 inhibitor, being developed as a treatment for eosinophilic esophagitis (EoE) within the Regulus program. Healthy subjects were administered single or multiple doses in a sequential escalating dosing schedule until the maximum planned dose of […]
Clinical Trials - October 23, 2023
Spago Nanomedical to initiate phase I/IIa study in Australia
The company’s application to start the clinical phase I/IIa study, Tumorad-01, with the candidate drug 177Lu-SN201 in cancer patients has been approved. The first patient is expected to be included shortly, states the company. “We are very excited and strongly motivated to now start the first clinical study with Tumorad. The study is designed in […]
Clinical Trials - October 18, 2023
Ultimovacs announces NIPU results presented at ESMO 2023
Ultimovacs has announced the results from the NIPU clinical trial, an investigator-initiated, randomized, multi-center, open-label Phase II clinical trial for second-line treatment in patients with malignant mesothelioma. The data presented as a late-breaking abstract at the ESMO Congress, shows that Ultimovacs’ cancer vaccine UV1, in combination with ipilimumab and nivolumab, demonstrated a statistically significant and […]
